These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 1306523

  • 21. Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas.
    Serri O, Beauregard H, Lesage J, Pedneault L, Comtois R, Jilwan N, Somma M, Vachon L, Brownell J.
    J Clin Endocrinol Metab; 1990 Sep; 71(3):682-7. PubMed ID: 2394774
    [Abstract] [Full Text] [Related]

  • 22. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
    Wang S, Wang A, Zhang Y, Zhu K, Wang X, Chen Y, Wu J.
    BMC Endocr Disord; 2021 Nov 23; 21(1):235. PubMed ID: 34814904
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Treatment of prolactinoma].
    Nadalon S, De Buhan B, Archambeaud-Mouveroux F, Fournier MP, Huc MC, Laubie B.
    Rev Med Interne; 1990 Nov 23; 11(2):172-80. PubMed ID: 2204979
    [Abstract] [Full Text] [Related]

  • 26. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
    Chattopadhyay A, Bhansali A, Masoodi SR.
    Pituitary; 2005 Nov 23; 8(2):147-54. PubMed ID: 16379032
    [Abstract] [Full Text] [Related]

  • 27. Management of Dopamine Agonist-Resistant Prolactinoma.
    Maiter D.
    Neuroendocrinology; 2019 Nov 23; 109(1):42-50. PubMed ID: 30481756
    [Abstract] [Full Text] [Related]

  • 28. The use of surgery for the treatment of prolactinomas.
    van't Verlaat JW.
    Acta Endocrinol (Copenh); 1993 Jul 23; 129 Suppl 1():34-7. PubMed ID: 8103958
    [Abstract] [Full Text] [Related]

  • 29. Giant prolactinomas: clinical management and long-term follow up.
    Shrivastava RK, Arginteanu MS, King WA, Post KD.
    J Neurosurg; 2002 Aug 23; 97(2):299-306. PubMed ID: 12186457
    [Abstract] [Full Text] [Related]

  • 30. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A.
    J Clin Endocrinol Metab; 2000 Sep 23; 85(9):3053-7. PubMed ID: 10999785
    [Abstract] [Full Text] [Related]

  • 31. Prolactin decrease and shift to a normal-like isoform profile during treatment with quinagolide in a patient affected by an invasive prolactinoma.
    Guido R, Valenti S, Foppiani L, De Martini D, Cossu M, Giusti M.
    J Endocrinol Invest; 1997 May 23; 20(5):289-93. PubMed ID: 9258810
    [Abstract] [Full Text] [Related]

  • 32. Clinical practice. Prolactinomas.
    Klibanski A.
    N Engl J Med; 2010 Apr 01; 362(13):1219-26. PubMed ID: 20357284
    [No Abstract] [Full Text] [Related]

  • 33. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy.
    Tyson D, Reggiardo D, Sklar C, David R.
    Am J Dis Child; 1993 Oct 01; 147(10):1057-61. PubMed ID: 8213676
    [Abstract] [Full Text] [Related]

  • 34. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Mar 01; 82(3):876-83. PubMed ID: 9062500
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 2000 Jun 01; 85(6):2247-52. PubMed ID: 10852458
    [Abstract] [Full Text] [Related]

  • 37. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P, Jaskuła M, Waśko R, Wołuń M, Sowiński J.
    Pol Arch Med Wewn; 2003 May 01; 109(5):489-95. PubMed ID: 14768178
    [Abstract] [Full Text] [Related]

  • 38. [Comparison of the therapeutic results of bromocriptine treatment of prolactin microadenoma and macroadenoma].
    Jin ZM, Shi YF, Chen GL.
    Zhonghua Nei Ke Za Zhi; 1990 Nov 01; 29(11):669-72, 702-3. PubMed ID: 2086009
    [Abstract] [Full Text] [Related]

  • 39. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC, Selcukbiricik OS, Tanrikulu S, Yarman S.
    Pituitary; 2016 Jun 01; 19(3):303-10. PubMed ID: 26830552
    [Abstract] [Full Text] [Related]

  • 40. Long-term treatment of macroprolactinomas with CV 205-502.
    Kvistborg A, Halse J, Bakke S, Bjøro T, Hansen E, Djøseland O, Brownell J, Jervell J.
    Acta Endocrinol (Copenh); 1993 Apr 01; 128(4):301-7. PubMed ID: 8098891
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.